Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01539447 · ClinicalTrials.gov registry record · Early Phase 1
Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy
A Early Phase 1 study of Heterotopic Ossification, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT01539447 is a Early Phase 1 study of Heterotopic Ossification that has completed, run by University of Utah. The registered enrollment target is 108 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01539447, a Early Phase 1 study of Heterotopic Ossification, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
In a brief summary the study would like to evaluate the effectiveness of Naproxen in preventing radiographically detected heterotopic ossification following hip arthroscopy for the treatment of femoroacetabular impingement.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Naproxen
Study Locations (1)
Utah
- University of Utah Orthopedics Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2012-01 |
| Est. Completion | 2022-03-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01539447
The ClinicalTrials.gov registry entry for NCT01539447 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heterotopic Ossification appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01539447 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT01539447 about?
NCT01539447 is a clinical study titled "Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy". In a brief summary the study would like to evaluate the effectiveness of Naproxen in preventing radiographically detected heterotopic ossification following hip arthroscopy for the treatment of femoroacetabular impingement.
What is the current status of trial NCT01539447?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 108 participants. The study started on 2012-01. Estimated completion is 2022-03-16.
What conditions does trial NCT01539447 study?
This clinical trial studies the following conditions: Heterotopic Ossification.
What interventions are being tested in trial NCT01539447?
The interventions under investigation include: placebo (DRUG), Naproxen (DRUG).
Who is sponsoring clinical trial NCT01539447?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01539447 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.